Further processing options
Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627).
Saved in:
Journal Title: | Journal of Clinical Oncology |
---|---|
Authors and Corporations: | , , , , , , , , |
In: | Journal of Clinical Oncology, 34, 2016, 15_suppl, p. TPS620-TPS620 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Society of Clinical Oncology (ASCO)
|
Subjects: |